MARKET

INVA

INVA

Innoviva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.35
+0.06
+0.37%
Closed 17:09 05/23 EDT
OPEN
16.43
PREV CLOSE
16.29
HIGH
16.67
LOW
16.20
VOLUME
1.01M
TURNOVER
--
52 WEEK HIGH
20.71
52 WEEK LOW
12.14
MARKET CAP
1.14B
P/E (TTM)
7.66
1D
5D
1M
3M
1Y
5Y
Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share
Benzinga · 1d ago
Innoviva to acquire Entasis Therapeutics for $2.20/share
Innoviva (NASDAQ:INVA) and Entasis Therapeutics Holdings (NASDAQ:ETTX) has entered into a definitive merger agreement under which Innoviva is to acquire all of the outstanding shares of Entasis at a price of $2.2/share
Seekingalpha · 1d ago
Innoviva (INVA) Surpasses Q1 Earnings and Revenue Estimates
Innoviva (INVA) delivered earnings and revenue surprises of 5% and 76.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 04/27 22:45
BRIEF-Innoviva Posts Quarterly EPS Of $0.20
reuters.com · 04/27 21:56
Innoviva Q1 EPS $0.20 Down From $0.84 YoY, Sales $90.06M Up From $85.52M YoY
Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.20 per share. This is a 76.19 percent decrease over earnings of $0.84 per share from the same period last year. The company reported $90.06 million in sales this
Benzinga · 04/27 21:25
Innoviva GAAP EPS of $0.20, revenue of $90.06M beats by $3.66M
Innoviva press release (NASDAQ:INVA): Q1 GAAP EPS of $0.20. Revenue of $90.06M (+5.3% Y/Y) beats by $3.66M.
Seekingalpha · 04/27 21:16
-- Earnings Flash (INVA) INNOVIVA Posts Q1 Revenue $90.1M
MT Newswires · 04/27 17:20
Is Bellus Health (BLU) Outperforming Other Medical Stocks This Year?
Here is how Bellus Health (BLU) and Innoviva (INVA) have performed compared to their sector so far this year.
Zacks · 04/25 13:40
More
No Data
Learn about the latest financial forecast of INVA. Analyze the recent business situations of Innoviva through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
50.00%Buy
0.00%Hold
50.00%Under-perform
0.00%Sell
Analyst Price Target
The average INVA stock price target is 20.50 with a high estimate of 28.00 and a low estimate of 13.00.
High28.00
Average20.50
Low13.00
Current 15.84
EPS
Actual
Estimate
0.230.450.670.90
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 313
Institutional Holdings: 78.12M
% Owned: 112.08%
Shares Outstanding: 69.70M
TypeInstitutionsShares
Increased
80
3.91M
New
34
1.57M
Decreased
68
4.14M
Sold Out
22
1.15M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.25%
Pharmaceuticals & Medical Research
-0.12%
Key Executives
Non-Executive Chairman/Independent Director
Odysseas Kostas
Chief Executive Officer
Pavel Raifeld
Chief Accounting Officer
Marianne Zhen
Independent Director
George Bickerstaff
Independent Director
Deborah Birx
Independent Director
Mark Dipaolo
Independent Director
Jules Haimovitz
Independent Director
Sarah Schlesinger
No Data
No Data
About INVA
Innoviva, Inc. is a company with a portfolio of royalties and other healthcare assets. Its royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including, RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO and ELLIPTA. RELVAR/BREO is a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS) and fluticasone furoate (FF). ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, VI. TRELEGY ELLIPTA a once-daily combination medicine consisting of an ICS, LAMA and LABA.

Webull offers kinds of Innoviva Inc stock information, including NASDAQ:INVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INVA stock methods without spending real money on the virtual paper trading platform.